Everest Medicines Ltd. (HK:1952)
:1952
1952 Stock Chart & Stats
HK$51.50
-HK$1.00(-2.24%)
At close: 4:00 PM EST
HK$51.50
-HK$1.00(-2.24%)
Day’s Range― - ―
52-Week RangeHK$31.70 - HK$77.55
Previous CloseN/A
Volume6.86M
Average Volume (3M)3.13M
Market Cap
HK$14.43B
Enterprise ValueHK$12.08B
Total Cash (Recent Filing)HK$1.59B
Total Debt (Recent Filing)HK$708.72M
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Sep 02, 2026EPS Estimate
-1.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding353,581,150
10 Day Avg. Volume4,149,807
30 Day Avg. Volume3,134,197
Financial Highlights & Ratios
PEG Ratio0.52
Price to Book (P/B)2.11
Price to Sales (P/S)6.72
P/FCF Ratio-64.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.63
Revenue Forecast (FY)HK$3.32B
Bulls Say, Bears Say
Bulls Say
Rapid Revenue GrowthNearly 95% top-line growth in 2025 signals rapid commercial traction and expanding market penetration. Sustained revenue expansion improves the odds of achieving scale, spreads fixed costs, enhances unit economics, and provides a firmer base to fund R&D and commercialization over the medium term.
High Gross MarginsApproximately 60% gross margin indicates robust product-level economics and pricing power. Durable margins give the company room to absorb SG&A and R&D as sales scale, increasing the likelihood of eventual operating leverage and sustainable profitability if revenue growth continues.
Improved Cash Burn And Strong Capital BaseOperating cash burn improved materially versus 2024 while the company retains a sizable equity base and low leverage (debt-to-equity ~0.17). This combination extends runway, reduces near-term refinancing pressure, and supports continued clinical and commercial investment over the next several quarters.
Bears Say
Ongoing UnprofitabilityNet margin around -17% in 2025 shows the business is still loss-making despite revenue growth. Persistent losses erode capital over time, restrict internal reinvestment, and require management to balance growth spending with the need to move toward sustainable profitability to preserve shareholder value.
Negative Operating And Free Cash FlowNegative OCF and FCF in 2025 mean the company is not yet self-funding and remains dependent on balance sheet reserves or external financing. Continued negative cash generation raises execution and dilution risk if capital markets tighten or if revenue growth slows before break-even.
Consistently Negative Return On EquityA history of negative ROE indicates the sizable equity base has not translated into profitable returns. Persistent capital inefficiency increases pressure to improve margins or operational returns, and may weaken investor confidence in management's ability to convert capital into long-term shareholder value.
Everest Medicines Ltd. News
1952 FAQ
What was Everest Medicines Ltd.’s price range in the past 12 months?
Everest Medicines Ltd. lowest stock price was HK$31.70 and its highest was HK$77.55 in the past 12 months.
What is Everest Medicines Ltd.’s market cap?
Everest Medicines Ltd.’s market cap is HK$14.43B.
When is Everest Medicines Ltd.’s upcoming earnings report date?
Everest Medicines Ltd.’s upcoming earnings report date is Sep 02, 2026 which is in 149 days.
How were Everest Medicines Ltd.’s earnings last quarter?
Everest Medicines Ltd. released its earnings results on Mar 25, 2026. The company reported -HK$0.137 earnings per share for the quarter, missing the consensus estimate of HK$0.114 by -HK$0.251.
Is Everest Medicines Ltd. overvalued?
According to Wall Street analysts Everest Medicines Ltd.’s price is currently Overvalued.
Does Everest Medicines Ltd. pay dividends?
Everest Medicines Ltd. does not currently pay dividends.
What is Everest Medicines Ltd.’s EPS estimate?
Everest Medicines Ltd.’s EPS estimate is -1.05.
How many shares outstanding does Everest Medicines Ltd. have?
Everest Medicines Ltd. has 353,581,150 shares outstanding.
What happened to Everest Medicines Ltd.’s price movement after its last earnings report?
Everest Medicines Ltd. reported an EPS of -HK$0.137 in its last earnings report, missing expectations of HK$0.114. Following the earnings report the stock price went down -4.725%.
Which hedge fund is a major shareholder of Everest Medicines Ltd.?
Currently, no hedge funds are holding shares in HK:1952
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Everest Medicines Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
1.46%
12-Months-Change
Fundamentals
Return on Equity
-11.43%
Trailing 12-Months
Asset Growth
44.26%
Trailing 12-Months
Company Description
Everest Medicines Ltd.
Everest Medicines Limited, a biopharmaceutical company, engages in discovery, licensing, clinical development, and commercialization of therapies to address critical unmet medical needs in Greater China and other Asia Pacific markets. Its pipeline products include eleven clinical-stage drug candidates for the treatment of oncology, immunology, cardio-renal, and infectious diseases. Everest Medicines Limited was incorporated in 2017 and is headquartered in Shanghai, China.
Technical Analysis
InnoCare Pharma Ltd.
―
Lepu Biopharma Co. Ltd. Class H
―
Keymed Biosciences, Inc.
―
CARsgen Therapeutics Holdings Ltd.
―
Shanghai Haohai Biological Technology Co., Ltd. Class H
―
Options Prices
Currently, No data available
---